Royalty Pharma has acquired a royalty interest from Neurimmune in AstraZeneca’s cliramitug, a Phase 3 drug targeting ATTR-CM, for up to $425 million including $125 million upfront. Cliramitug is designed to remove amyloid deposits in the heart, potentially transforming treatment for this fatal disease. The drug is in late-stage trials with results expected in 2028, and AstraZeneca projects peak sales of $3-5 billion. This deal strengthens Royalty Pharma’s portfolio in a growing market with significant unmet medical needs.
AstraZeneca announced that its drug Tezspire met all primary and key secondary goals in a late-stage trial for eosinophilic esophagitis, a chronic condition causing inflammation and difficulty swallowing. The trial involved 368 patients who received ...
AstraZeneca has priced a €2.55 billion bond issuance split into four fixed-rate tranches maturing between 2030 and 2038. The bonds, issued by its US subsidiary and guaranteed by the parent company, carry coupons ranging from 3.402% to 4.169%, reflect...
AstraZeneca faced a setback with the discontinuation of its volrustomig trial for non-small cell lung cancer, but strong clinical results for drugs like Tagrisso and Enhertu support its growth prospects. Investment firm CICC gave AstraZeneca an "Outp...
